Abstract
Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are rare and heterogeneous neoplasms with overall increasing incidence, but not an associated increase in survival rate over the past few decades. Tumors originate from at least 16 different cells of diffuse endocrine system (DES), scattered through mucosa of gastrointestinal tract. They are mainly sporadic, but sometimes exhibit familial inheritance. Tumors often preserve the ability to synthesize, store and secrete numerous hormones and biogenic amines which sometimes lead to distinct hypersecretory and clinically recognizable syndromes (such as carcinoid, Zollinger-Ellison, WDHA etc.).1 The resulting clinical symptoms are generally well controlled by somatostatin analogs and/or interferon-┙.2
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
